Company Overview
Indegene Limited (BSE: 544172, NSE: INDGN) reported strong financial performance for FY 2025-26 with significant growth and strategic developments.
Financial Performance
Indegene achieved consolidated revenue of ₹35,105 million in FY26, representing 24% year-on-year growth from ₹28,393 million in FY25. Net profit stood at ₹4,011 million, with basic EPS of ₹16.72. The company reported standalone revenue of ₹12,206 million with net profit of ₹2,119 million. The Board recommended a final dividend of ₹2.25 per equity share, subject to shareholder approval at the 28th Annual General Meeting, with potential cash outflow of approximately ₹542 million.
Business Expansion and Acquisitions
The company completed four strategic acquisitions during FY26, most notably BioPharm Parent Holding Inc. for ₹8,821 million, which resulted in recognition of ₹6,429 million goodwill. Other acquisitions included MJL Communications Group Ltd, Warn & Co Limited, and Cake Kommunikations, significantly expanding the company's commercialization capabilities and global footprint. The acquisitions contributed to the reorganization into two reportable segments: Enterprise Commercial Solutions (70% of revenue) and Enterprise Medical Solutions (26% of revenue).
28th Annual General Meeting
Indegene will hold its 28th AGM on 13 August 2026 through video conference. Key agenda items include adoption of financial statements, declaration of final dividend, re-appointment of retiring directors (Manish Gupta and Dr. Sanjay Suresh Parikh), and appointment of Jill Mary De Simone as Independent Director. The record date for dividend is 31 July 2026, with e-voting scheduled from 10-12 August 2026.
Regulatory and Compliance Matters
The company received a draft transfer pricing order proposing an adjustment of ₹1,114 million for AY2023-24 and is pursuing resolution through Mutual Agreement Procedure. Indegene maintained full compliance with SEBI Listing Regulations and corporate governance requirements, including Code of Conduct affirmations from all directors and senior management. The company also recognized a litigation provision of ₹203 million for a TCPA lawsuit settlement in the US.
ESG and Sustainability Performance
Indegene demonstrated strong ESG commitment with SBTi-validated emissions targets, achieving 20.63% reduction in Scope 1 and 2 emissions and 68.68% reduction in Scope 3 emissions against FY28 targets. The company reported 98.47% export revenue and maintained 18.18% female representation on its board. ESG ratings included CDP Score 'B', EcoVadis Silver Medal (75), and NSE ESG Score of 80 (Leader category).
Shareholder and Corporate Governance
Shareholding pattern as of 31 March 2026 showed 143,973 shareholders with major holdings by Nadathur Fareast Pte. Ltd (21.88%), Manish Gupta (8.91%), and Dr. Rajesh B. Nair (7.14%). The company obtained shareholder approvals via three postal ballots during FY25-26 for director reappointments and variation in IPO proceeds utilization. IPO fund utilization stood at 97.6% with ₹172 million remaining unutilized.
Auditor's Report and Financial Controls
Deloitte Haskins & Sells issued unmodified opinions on both standalone and consolidated financial statements, confirming true and fair presentation in accordance with Ind AS. The auditor also expressed unmodified opinion on the adequacy and operating effectiveness of the company's internal financial controls.
Subsequent Events and Outlook
The company evaluated events up to 29 April 2026 and identified no material adjusting events other than the dividend proposal. Indegene continues to focus on strategic growth through organic expansion and targeted acquisitions while maintaining robust corporate governance and regulatory compliance.